Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:MEOBF
CUSIPN/A
PhoneN/A
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares470,600,000
Market Cap$634.14 million
Mesoblast (OTCMKTS:MEOBF) Frequently Asked Questions
What is Mesoblast's stock symbol?
Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."
Who are some of Mesoblast's key competitors?
Some companies that are related to Mesoblast include MorphoSys (MOR), Almirall (LBTSF), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Unity Biotechnology (UBX), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1) and Oxford BioMedica (OXB).
Who are Mesoblast's key executives?
Mesoblast's management team includes the folowing people:
- Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 61)
- Mr. Josh Muntner, Chief Financial Officer (Age 49)
- Dr. Suzanne Lipe BSc (Hons), Ph.D., LLB, VP of Operations (Age 68)
- Mr. Jonathan Richard Symonds, Head of Corp. Fin. & Strategy (Age 59)
- Mr. Peter Howard BSc, LLB (Hons), Gen. Counsel & Corp. Exec. (Age 50)
Has Mesoblast been receiving favorable news coverage?
News headlines about MEOBF stock have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mesoblast earned a media and rumor sentiment score of 0.18 on Accern's scale. They also gave media headlines about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Mesoblast.
How do I buy shares of Mesoblast?
Shares of MEOBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mesoblast's stock price today?
One share of MEOBF stock can currently be purchased for approximately $1.17.
How big of a company is Mesoblast?
Mesoblast has a market capitalization of $634.14 million.
MarketBeat Community Rating for Mesoblast (OTCMKTS MEOBF)
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MEOBF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEOBF will underperform the S&P 500 over the long term. You may vote once every thirty days.
